



The TIMI Trials

TIMI IIB

OBJECTIVES:

To compare the effects of an invasive vs. conservative strategy following thrombolysis with rtPA among patients with ST elevation myocardial infarction.

To compare the effect of immediate vs. delayed (6 days) metoprolol therapy among patients with ST elevation myocardial infarction treated with rtPA (a substudy of the TIMI II trial).

1. **The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-627.**
2. **Roberts R, Rogers WJ, Mueller HS, for the TIMI Investigators. Immediate versus deferred B-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422-437.**
3. Kayden DS, Mattera JA, Zaret BL, Wackers FJT. Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging. J Nuc Med 1988;29:1865-7.
4. Gibbons RJ, Verani MS, Behrenbeck T, Pellikka PA, O'Connor MK, Mahmarian JJ, Chesebro JH, Wackers FJ. Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 1989;80:1277-86.
5. Gore JM, Corrao JM, Goldberg RJ, Ball SP, Weiner BH, Aghababian RV, Dalen JE. Feasibility and safety of emergency interhospital transport of patients during early hours of acute myocardial infarction. Ach Intern Med 1989;149:353-5.
6. Sharkey SW, Brunette DD, Ruiz E, Hession WT, Wysham DG, Goldengerg IF, Hodges M. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989;262:3171-3174.
7. Wackers FJT, Gibbons RJ, Verani MS, Kayden DS, Pellikka PA, Behrenbeck T, Mahmarian JJ, Zaret BL. Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: Efficacy for noninvasive assessment of thrombolytic therapy. J Am Coll Cardiol 1989;14:861-73.
8. Feit F, Mueller HS, Braunwald E, Ross R, Hodges M, Herman MV, Knatterud GL, and the TIMI Research Group. Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial: Outcome comparison of a "conservative strategy" in community versus tertiary hospitals. J Am Coll Cardiol 1990;16:1529-1534.
9. Hillis LD, Forman S, Braunwald E, and the Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990;16:313-5.
10. Johnson LL, Seldin DW, Keller AM, Wall RM, Bhatia K, Bingham CO, III., Tregallo ME. Dual isotope thallium and Indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic risk. Circulation 1990;81:37-45.
11. Kayden DS, Wackers FJT, Zaret BL. Silent left ventricular dysfunction during routine activity after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1990;15:1500-7.
12. Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Fibrin fragment D-Dimer and fibrinogen B-beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 1990;76:1341-1348.
13. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore J, Hillis D, Lambrew CT, Leigoff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial - Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial. Ann Intern Med 1991;115:256-65.

14. Gore JM, Sloan M, Price T, Young Randall AM, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML, and the TIMI Investigators. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. *Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation* 1991;83:448-59.
15. Rogers WJ, Babb JD, Baim DS, Chesebro JH, Gore JM, Roberts R, Williams DO, Frederick M, Passamani ER, Braunwald E, for the TIMI II Investigators. Selective versus routine predischARGE coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. *J Am Coll Cardiol* 1991;17:1007-1016.
16. Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II. *Circulation* 1991;84:II-230.
17. Zaret B, Wackers FJ, Terrin M, Ross R, Knatterud G, Braunwald E, for the TIMI Investigators. Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the pre-thrombolytic era? Results of the TIMI II Trial. *J Am Coll Cardiol* 1991;17:214A.
18. Baim DS, Diver DJ, Feit F, Greenberg MA, Holmes DR, Weiner BH, Williams DO, Schweiger MJ, Brown BG, Frederick MM, Knatterud GL, Braunwald E, for the TIMI II Investigators. Coronary angioplasty performed within the Thrombolysis in Myocardial Infarction (TIMI II) Study. *Circulation* 1992;85:93-105.
19. Berger PB, Ruocco NA, Jr., Ryan TJ, Frederick MM, Jacobs AK, Faxon DP, for the TIMI Investigators. The incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: Results from TIMI II. *J Am Coll Cardiol* 1992;20:533-40.
20. Kleiman NS, Terrin M, Mueller H, Chaitman B, Roberts R, Knatterud GL, Solomon R, McMahon RP, Braunwald E, and the TIMI Investigators. Mechanism of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Investigation Phase II (TIMI II) Study. *J Am Coll Cardiol* 1992;19:1129-35.
21. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for the TIMI Investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II. *Circulation* 1992;85:1254-64.
22. Ruocco NA, Jr., Bergelson BA, Jacobs AK, Frederick MM, Faxon DP, Ryan TJ for the TIMI Investigators. Invasive versus conservative strategy post thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II). *J Am Coll Cardiol* 1992;20:1445-51.
23. Tofler GH, Muller JE, Stone PH, Forman S, Solomon RE, Knatterud GL, Braunwald E, and the TIMI Research Group. Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI) Study Group. *J Am Coll Cardiol* 1992;20:1049-55.
24. Williams DO, Braunwald E, Knatterud G, Babb J, Bresnahan J, Greenberg M, Raizner A, Wasserman A, Robertson T, Ross R, and TIMI Investigators. One-year results of the Thrombolysis in Myocardial Infarction Investigation (TIMI) phase II trial. *Circulation* 1992;85:533-542.
25. Zaret BL, Wackers FJT, Terrin ML, Ross R, Weiss M, Slater J, Morrison J, Bourge RC, Passamani E, Knatterud G, Braunwald E, for the TIMI Investigators. Assessment of global and regional left ventricular performance at rest and during exercise following thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI II) Study. *Am J Cardiol* 1992;69:1-9.
26. Berger PB, Ruocco NA, Ryan TJ, Jacobs AK, Zaret BL, Wackers FJ, Frederick MM, Faxon DP, and the TIMI Research Group. The frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy: (Results from the Thrombolysis in Myocardial Infarction (TIMI) II Trial). *Am J Cardiol* 1993;71:1148-1152.
27. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ, and the TIMI Investigators. The incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with rt-PA: Results from the TIMI II trial. *J Am Coll Cardiol* 1993;22:1773-9.
28. Chaitman BR, McMahon RP, Terrin M, Younis LT, Shaw LJ, Weiner DA, Frederick MM, Knatterud GL, Sopko G, Braunwald E, for the TIMI Investigators. Impact of treatment strategy on predischARGE exercise test in the Thrombolysis In Myocardial Infarction (TIMI) II trial. *Am J Cardiol* 1993;71:131-138.

29. Taylor HA, Chaitman BR, Rogers WJ, Kern MJ, Terrin ML, Aguirre FV, Sopko G, McMahon R, Ross RN, Bovill EC, TIMI Investigators. Race and Prognosis after myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. *Circulation* 1993;88[part I]:1484-94.
30. Terrin ML, Williams DO, Kleiman NS, Willerson J, Mueller HS, Desvignes-Nickens P, Forman SA, Knatterud GL, Braunwald E, for the TIMI II Investigators. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. *J Am Coll Cardiol* 1993;22:1763-72.
31. Simoons ML, Maggioni AP, Knatterud G, Leimingerger JD, de Jaegere R, van Domburg R, Boersma E, Franzosi MG, Schroder R, Braunwald E. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. *Lancet* 1993;342:1523-8.
32. Aguirre FV, McMahon RP, Mueller H, Kleiman NS, Kern MJ, Desvigne-Nickens P, Hamilton WR, Chaitman BR, for the TIMI II Investigators. Impact of age on clinical outcome and postlytic management strategies in patients treated with thrombolytic therapy. Results from the TIMI II study. *Circulation* 1994;90:78-86.
33. Becker RC, Terrin M, Ross R, Knatterud GL, Desvigne-Nickens P, Gore JM, Braunwald E, and the Thrombolysis in Myocardial Infarction Investigators. Comparison of clinical outcomes for women and men after acute myocardial infarction. *Ann Intern Med* 1994;120:638-45.
34. Cox DA, Rogers WJ, Aguirre FV, Forman S, Solomon R, Zaret BL, and the TIMI Investigators. Effect on outcome of the presence or absence of chest pain at initiation of tissue plasminogen activator therapy in acute myocardial infarction. *Am J Cardiol* 1994;73:729-736.
35. Schweiger MJ, McMahon RP, Terrin ML, Ruocco NA, Porway MN, Wiseman AH, Knatterud GL, Braunwald E, for the TIMI Investigators. Comparison of patients with < 60% to > 60% diameter narrowing of the myocardial infarct-related artery after thrombolysis. *Am J Cardiol* 1994;74:105-110.
36. Aguirre FV, Younis LT, Chaitman BR, Ross AM, McMahon RP, Kern MJ, Berger PB, Sopko G, Rogers WJ, Shaw L, Knatterud G, Braunwald E, for the TIMI II Investigators. Early and 1-year clinical outcome of patients' evolving non-Q wave versus Q-wave myocardial infarction after thrombolysis: Results from the TIMI II Study. *Circulation* 1995;91:2541-2548.
37. Gersh BJ, Chesebro JH, Braunwald E, Lambrew C, Passamani E, Solomon RE, Ross AM, Ross R, terrin ML, Knatterud GL, and the TIMI II Investigators. Coronary artery bypass surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II). *J Am Coll Cardiol* 1995;25:395-402.
38. Hall C, Cannon CP, Forman S, Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) II Investigators. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. *J Am Coll Cardiol* 1995;26:1452-1456.
39. Mueller HS, Forman SA, Manegus MA, Cohen LS, Knatterud GL, Braunwald E, for the TIMI Investigators. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Clinical Trial. *J Am Coll Cardiol* 1995;26:900-907.
40. Sloan MA, Price TR, Petite CK, Randall AMY, Solomon RE, Terrin ML, Gore J, Collen D, Kleiman N, Feit F, Babb J, Herman M, Roberts WC, Sopko G, Bovill E, Forman S, Knatterud GL, for the TIMI Investigators. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. *Neurology* 1995;45:649-658.
41. Zaret BL, Wackers FJT, Terrin ML, Forman SA, Williams DO, Knatterud GL, Braunwald E, for the TIMI Study Group. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II study. *J Am Coll Cardiol* 1995;26:73-79.
42. Callas PW, Tracy RP, Bovill EG, Cannon C, Thompson B, Mann KG. The association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) trial. *J Thromb Thrombolysis* 1998;5:53-60.
43. Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown RG, Collen D, Mahan E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO, Zaret BL. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. *Am Heart J* 1998;135:29-37.